stockportfolio.pro
AtriCure, Inc. (ATRC)
Healthcare · Medical Instruments & Supplies · NasdaqGM
AtriCure, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $155.11M | $174.72M | $201.63M | $230.81M | $206.53M | $274.33M | $330.38M | $399.25M | $465.31M | $534.53M |
| Gross profit | $111.10M | $126.16M | $147.12M | $170.34M | $149.31M | $205.86M | $245.94M | $300.37M | $347.52M | $400.78M |
| Net income | $-33.34M | $-26.89M | $-21.14M | $-35.19M | $-48.16M | $50.20M | $-46.47M | $-30.44M | $-44.70M | $-11.45M |
| Net margin | -21.5% | -15.4% | -10.5% | -15.2% | -23.3% | 18.3% | -14.1% | -7.6% | -9.6% | -2.1% |
Source: AtriCure, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
What growth is priced into ATRC stock?
At today's market cap of $1.40B, AtriCure, Inc. is priced for free-cash-flow growth of about 14.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $42.28M from the FY ending 2025-12-31). For comparison, revenue 20.9%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 17 years of AtriCure, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ATRC in your portfolio →
AtriCure, Inc. financial history by metric
About AtriCure, Inc.
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
AtriCure, Inc. — frequently asked questions
What is AtriCure, Inc.'s revenue?
AtriCure, Inc. (ATRC) reported revenue of $534.53M for fiscal year 2025, up 14.9% from the prior year, according to its SEC filings.
Is AtriCure, Inc. profitable?
No — ATRC reported a net loss of $-11.45M in fiscal 2025.
What is ATRC's P/E ratio?
AtriCure, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is AtriCure, Inc. growing?
ATRC's revenue grew at roughly 20.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does AtriCure, Inc. have?
As of fiscal year 2025, ATRC carried roughly $61.87M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is AtriCure, Inc.'s gross margin?
ATRC's gross margin was 75.0% in fiscal 2025 — gross profit of $400.78M on revenue of $534.53M.
What is AtriCure, Inc.'s market cap?
AtriCure, Inc. (ATRC) has a market capitalization of about $1.40B, based on the latest data in our nightly-refreshed cache.
When does AtriCure, Inc.'s fiscal year end?
ATRC's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into ATRC stock?
At today's market cap of $1.40B, AtriCure, Inc. is priced for free-cash-flow growth of about 14.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $42.28M from the FY ending 2025-12-31). For comparison, revenue 20.9%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from AtriCure, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.